Antineoplastic Combined Chemotherapy Protocols

Publication Title: 
Nederlands Tijdschrift Voor Geneeskunde

Non-Hodgkin lymphoma is seen in approximately 5% of patients with AIDS. In recent years, the incidence has increased due to an extension of the average lifespan of HIV-infected individuals. In this article we describe the histological and clinical features of 45 patients with HIV-related non-Hodgkin lymphoma seen at the Academic Medical Centre between 1984 and 1991. There were 43 men and 2 women with a median age of 40 years. Most patients had high-grade B-cell lymphoma; 85% had extranodal sites. Prognosis was poor: overall median survival was only 3.8 months.

Author(s): 
Kersten, M. J.
Mertens, M. J.
Pals, S. T.
Reiss, P.
van Oers, M. H.
Publication Title: 
Cancer Investigation

Paclitaxel is an active agent for adenocarcinomas and squamous cell carcinomas of the esophagus and is a radiation sensitizer. We sought to investigate the toxicity and complete response rate of paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Forty-one patients with esophageal cancer were studied, 29 with adenocarcinomas and 12 with squamous cell cancers. Twelve patients had tumor extension into the proximal stomach and/or abdominal adenopathy.

Author(s): 
Safran, H.
Gaissert, H.
Akerman, P.
Hesketh, P. J.
Chen, M. H.
Moore, T.
Koness, J.
Graziano, S.
Wanebo, H. J.
Publication Title: 
Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer

PURPOSE: Psychological responses to cancer are widely believed to affect survival. We investigated associations between hope, optimism, anxiety, depression, health utility and survival in patients starting first-line chemotherapy for metastatic colorectal cancer. METHODS: Four hundred twenty-nine subjects with metastatic colorectal cancer in a randomised controlled trial of chemotherapy completed baseline questionnaires assessing the following: hopefulness, optimism, anxiety and depression and health utility.

Author(s): 
Schofield, Penelope E.
Stockler, M. R.
Zannino, D.
Tebbutt, N. C.
Price, T. J.
Simes, R. J.
Wong, N.
Pavlakis, N.
Ransom, D.
Moylan, E.
Underhill, C.
Wyld, D.
Burns, I.
Ward, R.
Wilcken, N.
Jefford, M.
Publication Title: 
Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology

Fifty-one children 6-17 years of age rated the severity of nausea, vomiting, and the extent to which chemotherapy bothered them during each course of chemotherapy. Sixteen patients had no symptoms and the doses administered to 16 others were not constant so that matched courses could not be assessed. After baseline measurement of two matched courses, the remaining 19 patients were randomized to receive hypnosis or supportive counseling during two more matched courses. An additional course with no intervention was assessed in half of the patients.

Author(s): 
Zeltzer, L.
LeBaron, S.
Zeltzer, P. M.
Publication Title: 
The American Journal of Clinical Hypnosis
Author(s): 
Kaye, J. M.
Publication Title: 
The International Journal of Clinical and Experimental Hypnosis

This paper presents the case of a 6.5-year-old girl with malignant astrocytoma of the left brain hemisphere. During the course of her chemotherapy treatment, severe vomiting developed to the degree that on several occasions she became dehydrated. Discontinuation of chemotherapy was being considered when she was referred for hypnotherapy. Despite severe neurological impairments which excluded many traditional techniques, hypnosis was successful in eliminating emesis. Hypnosis was also utilized to decrease pain and to improve sleep patterns.

Author(s): 
LaClave, L. J.
Blix, S.
Publication Title: 
Pediatrics

Fifty-four pediatric cancer patients were studied to determine the relative efficacy of two forms of behavioral intervention for reducing chemotherapy-related distress. Following baseline assessment, subjects were randomly assigned to receive either hypnosis, non-hypnotic distraction/relaxation, or attention placebo (control) during the subsequent identical chemotherapy course. Observational and interview measures of anticipatory and postchemotherapy nausea, vomiting, distress, and functional disruption served as outcome data.

Author(s): 
Zeltzer, L. K.
Dolgin, M. J.
LeBaron, S.
LeBaron, C.
Publication Title: 
Oncology (Williston Park, N.Y.)

Nausea and vomiting associated with chemotherapy most commonly occur after administration of the drug regimen, but a substantial proportion of patients also develop these symptoms in anticipation of treatment, after one or more courses of chemotherapy have been given. Currently available pharmacologic agents are unable to provide complete protection from either anticipatory or post-treatment nausea and emesis associated with cancer chemotherapy.

Author(s): 
Morrow, G. R.
Hickok, J. T.
Publication Title: 
Anticancer Research

BACKGROUND: Butyric acid is a short chain fatty acid produced by large bowel bacterial flora. It serves as an antiinflammatory agent and nutrient for normal colon cells. Butyric acid has also been shown to induce apoptosis in colon and many other cancer cells. Artemisinin is a compound extracted from the wormwood Artemisia annua L. It has been shown to selectively kill cancer cells in vitro and to be effective in treating animal and human cancer. We and others have found that the artemisinin analog, dihydroartemisinin (DHA), kills cancer cells by apoptosis.

Author(s): 
Singh, Narendra P.
Lai, Henry C.
Publication Title: 
Zhong Xi Yi Jie He Xue Bao = Journal of Chinese Integrative Medicine

OBJECTIVE: To our knowledge, there has been no clinical report of artesunate in the treatment of lung cancer. This study was designed to compare the efficacy and toxicity of artesunate combined with NP (a chemotherapy regimen of vinorelbine and cisplatin) and NP alone in the treatment of advanced non-small cell lung cancer (NSCLC). METHODS: One hundred and twenty cases of advanced NSCLC were randomly divided into simple chemotherapy group (control group, n=60) and combined artesunare with chemotherapy group (trial group, n=60).

Author(s): 
Zhang, Zhu-Yi
Yu, Shi-Qing
Miao, Li-Yun
Huang, Xiao-Ying
Zhang, Xiao-ping
Zhu, Yu-Ping
Xia, Xiao-hong
Li, Dan-Qi

Pages

Subscribe to RSS - Antineoplastic Combined Chemotherapy Protocols